CNTY-103 / Century Therap - LARVOL DELTA

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire) - "Century Therapeutics...announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026. The resulting changes include de-prioritizing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will prioritize key programs, including one follow-on product candidate for lymphoma, CNTY-102, and CNTY-107, a product candidate for Nectin-4+ tumors. In addition, Century will continue its partnered programs with Bristol Myers Squibb with no impact to previous guidance on timelines."

Pipeline update • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates (GlobeNewswire) - "Upcoming Milestones...Current Good Manufacturing Practice (cGMP) manufacturing facility expected to be operational in 2022; CNTY-101 IND filing remains on track for mid-2022. Subject to U.S. FDA acceptance of its IND application, the Company plans to initiate the Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma in 2022; Expect to submit an IND for CNTY-103 in 2023. CNTY-103 is Century’s first solid tumor candidate for glioblastoma."

Commercial • IND • New P1 trial • Glioblastoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor